Pacira Seeks Proxy Support After Q1 Sales Total $176.3M, Stock Up 30%
Pacira has mailed a letter urging shareholders to vote "FOR" its three board nominees at the June 9 meeting, highlighting its 5x30 strategy has driven a 30% stock increase and Q1 topline growth beating consensus. EXPAREL sales reached $143.3 million, ZILRETTA $26.8 million (+15%), and iovera° $6.2 million (+21%).
1. Proxy Fight and Shareholder Letter
Pacira mailed a letter to stockholders ahead of its June 9, 2026 Annual Meeting urging a vote "FOR" its three board nominees on the BLUE proxy card to safeguard the 5x30 strategy and ongoing growth trajectory.
2. Strategic 5x30 Plan Performance
CEO Frank D. Lee’s 5x30 strategy, launched in January 2025, targets patients served, product revenue, profitability, pipeline development and partnerships, and has driven a more than 30% rise in Pacira’s stock price.
3. Q1 2026 Financial Results
Pacira reported Q1 2026 net sales of $143.3 million for EXPAREL, $26.8 million (up 15%) for ZILRETTA, and $6.2 million (up 21%) for iovera°, delivering topline growth ahead of consensus estimates.
4. Activist Alternative Plan
Activist investor DOMA Perpetual Capital Management has proposed replacing the board with three nominees lacking public company experience, broad cost cuts, CEO replacement and an immediate sale process, which Pacira warns could disrupt its strategic plan.